October 19, 2021
Video
Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.
October 19, 2021
Video
An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.
October 19, 2021
Video
Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.
October 19, 2021
Video
Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.
October 19, 2021
Video
A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.
October 19, 2021
Video
Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.